1. Home
  2. PFSA vs RANI Comparison

PFSA vs RANI Comparison

Compare PFSA & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFSA
  • RANI
  • Stock Information
  • Founded
  • PFSA 2009
  • RANI 2012
  • Country
  • PFSA United States
  • RANI United States
  • Employees
  • PFSA N/A
  • RANI N/A
  • Industry
  • PFSA Medical/Dental Instruments
  • RANI Medicinal Chemicals and Botanical Products
  • Sector
  • PFSA Health Care
  • RANI Health Care
  • Exchange
  • PFSA Nasdaq
  • RANI Nasdaq
  • Market Cap
  • PFSA 25.1M
  • RANI 23.2M
  • IPO Year
  • PFSA N/A
  • RANI 2021
  • Fundamental
  • Price
  • PFSA $0.50
  • RANI $0.55
  • Analyst Decision
  • PFSA
  • RANI Strong Buy
  • Analyst Count
  • PFSA 0
  • RANI 4
  • Target Price
  • PFSA N/A
  • RANI $7.75
  • AVG Volume (30 Days)
  • PFSA 7.9M
  • RANI 1.1M
  • Earning Date
  • PFSA 01-01-0001
  • RANI 08-07-2025
  • Dividend Yield
  • PFSA N/A
  • RANI N/A
  • EPS Growth
  • PFSA N/A
  • RANI N/A
  • EPS
  • PFSA N/A
  • RANI N/A
  • Revenue
  • PFSA $75,000.00
  • RANI $1,200,000.00
  • Revenue This Year
  • PFSA N/A
  • RANI N/A
  • Revenue Next Year
  • PFSA N/A
  • RANI N/A
  • P/E Ratio
  • PFSA N/A
  • RANI N/A
  • Revenue Growth
  • PFSA 150.00
  • RANI N/A
  • 52 Week Low
  • PFSA $0.46
  • RANI $0.39
  • 52 Week High
  • PFSA $5.50
  • RANI $3.75
  • Technical
  • Relative Strength Index (RSI)
  • PFSA N/A
  • RANI 53.01
  • Support Level
  • PFSA N/A
  • RANI $0.50
  • Resistance Level
  • PFSA N/A
  • RANI $0.59
  • Average True Range (ATR)
  • PFSA 0.00
  • RANI 0.04
  • MACD
  • PFSA 0.00
  • RANI 0.00
  • Stochastic Oscillator
  • PFSA 0.00
  • RANI 63.16

About PFSA Profusa Inc. Common Stock

Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: